Another sucessful completion of inspection at Caplin
ANVISA- Brazil conducted an inspection of Caplin Steriles’ injectable and ophthalmic manufacturing facility located at Gummidipoondi. The inspection was conducted between August 12th and 16th, 2024 and concluded with zero observations
This will help Caplin to get into Brazilian markets and eventually to Chile and Peru. Thier business model is based on opening of warehouses in the country they enter and establish distribution, this sucessful inspection means that they will be able to cater the brazilain markets with more products of better quality and when their products portfolio reaches 30+ they can open a warehouse in Brazil ( with fewer products warehouse in not economically viable according to the management )
Quarterly results also robust and management commentary also encouraging
Disc : Not a buy/sell recommendation. Not Sebi registered.( Invested )
| Subscribe To Our Free Newsletter |
